

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): A controlled release coating for an implantable medical device comprising:

a terpolymer-bipolymer blend having a total solubility parameter (δ_T) approximately equal to a bioactive agent's solubility parameter (δ) and wherein δ_T and δ is between $15 \text{ J}^{1/2}/\text{cm}^{3/2}$ to $25 \text{ J}^{1/2}/\text{cm}^{3/2}$.

Claim 2 (original): The controlled release coating according to claim 1 wherein said coating has a glass transition point (T_g) between approximately -20°C and 50°C .

Claim 3 (currently amended): The controlled release coating according to claim 1 wherein said terpolymer comprises relative weight percent concentrations of monomer subunits consisting ~~essentially~~ of vinyl acetate (VAc), alkyl methacrylate (AMA) and n-vinyl pyrrolidone (NVP) and said bipolymer comprises relative weight percent concentrations of monomer subunits consisting ~~essentially~~ of VAc and AMA.

Claim 4 (currently amended): The controlled release coating according to claim 3 wherein said relative weight percent concentrations of said monomer subunits in said terpolymer comprises from 7-30% (VAc), 40-~~75~~ 74% (AMA) and 19-30% (NVP).

Claim 5 (original): The controlled release coating according to claim 3 wherein said relative weight percent concentrations of said monomer subunits in said bipolymer comprises from 5-70% VAc and from 30-95% AMA

Claim 6 (currently amended): The controlled release coating according to claim 3 wherein said alkyl of said alkyl methacrylate is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, and hexyl.

Claim 7 (currently amended): The controlled release coating according to ~~anyone~~ any one of claims 1 through 6 wherein said δ_T is approximately 15 to 21 and said polymer blend comprises from 40% to 80% bipolymer and from 20% to 60% terpolymer.

Claim 8 (currently amended): The controlled release coating according to ~~anyone~~ any one of claims 1-6 wherein said bipolymer has a lower Tg than said terpolymer.

Claim 9 (currently amended): The controlled release coating according to claim 1 wherein said bioactive agent is selected from the group consisting of anti-proliferatives including, but not limited to, macrolide antibiotics, ~~including~~ FKBP 12 binding compounds, estrogens, chaperone inhibitors, protease inhibitors, protein-tyrosine kinase inhibitors, peroxisome proliferator-activated receptor gamma ligands (PPAR γ), hypothemycin, nitric oxide, bisphosphonates, epidermal growth factor inhibitors, antibodies, antibiotics, proteasome inhibitors anti-sense nucleotides and transforming nucleic acids.

Claim 10 (original): The controlled release coating according to claim 9 wherein said antiproliferative is a FKBP 12 binding compound.

Claim 11 (original): The controlled release coating according to claim 10 wherein said FKBP 12 binding compound is a macrolide antibiotic.

Claim 12 (currently amended): The controlled release coating according to claim 11 wherein said macrolide antibiotic is ~~A-19~~ rapamycin or ~~A-20~~ everolimus.

Claim 13 (original): A vascular stent comprising:
a structure comprising a material, said material having a coating thereon comprised of a hydrophobic polymer;
a bioactive agent-containing terpolymer-bipolymer blend over said hydrophobic polymer wherein the difference between the solubility parameters of said terpolymer-bipolymer blend and said bioactive agent is no greater than $10 \text{ J}^{1/2}/\text{cm}^{3/2}$ and the total solubility parameter (δ_T) of said bioactive agent-containing terpolymer-bipolymer blend is no greater than $25 \text{ J}^{1/2}/\text{cm}^{3/2}$.

Claim 14 (currently amended): The vascular stent according to claim 13 wherein said hydrophobic polymer is parylene ~~or a parylene derivative~~.

Claim 15 (currently amended): The vascular stent according to claim 13 wherein said terpolymer comprises relative weight percent concentrations of monomer subunits consisting ~~essentially~~ of vinyl acetate (VAc), alkyl methacrylate (AMA) and n-vinyl pyrrolidone (NVP) and said bipolymer comprises relative weight percent concentrations of monomer subunits consisting ~~essentially~~ of VAc and AMA.

Claim 16 (currently amended): The vascular stent according to claim 15 wherein said relative weight percent concentrations of said monomer subunits in said terpolymer comprises from 7-30% (VAc), 40-~~75~~ 74% (AMA) and 19-30% (NVP).

Claim 17 (original): The vascular stent according to claim 13 wherein said relative weight percent concentrations of said monomer subunits in said bipolymer comprises from 5-70% VAc and from 30-95% AMA

Claim 18 (currently amended): The vascular stent according to claim 15 wherein said alkyl of said alkyl methacrylate is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, and hexyl.

Claim 19 (currently amended): The vascular stent according to ~~anyone~~ any one of claims 13 through 18 wherein said δT is approximately 15 to 21 and said polymer blend comprises from 40% to 80% bipolymer and from 20% to 60% terpolymer.

Claim 20 (currently amended): The vascular stent according to ~~anyone~~ any one of claims 13-18 wherein said bipolymer has a lower Tg than said terpolymer.

Claim 21 (currently amended): The vascular stent according to claim 13 wherein said bioactive agent is selected from the group consisting of anti-proliferatives including, but not limited to, macrolide antibiotics, ~~including~~ FKBP 12 binding compounds, estrogens, chaperone inhibitors, protease inhibitors, protein-tyrosine kinase inhibitors, peroxisome proliferator-activated receptor gamma ligands (PPAR γ), hypothemycin, nitric oxide, bisphosphonates,

epidermal growth factor inhibitors, antibodies, antibiotics, proteasome inhibitors anti-sense nucleotides and transforming nucleic acids.

Claim 22 (previously presented): The vascular stent according to claim 21 wherein said antiproliferative is a FKBP 12 binding compound.

Claim 23 (previously presented): The vascular stent according to claim 22 wherein said FKBP 12 binding compound is a macrolide antibiotic.

Claim 24 (currently amended): The vascular stent according to claim 23 wherein said macrolide antibiotic is ~~A-19~~ rapamycin or ~~A-20~~ everolimus.